120 related articles for article (PubMed ID: 12840709)
1. Induction-maintenance antiretroviral strategies to reduce long-term toxicity.
Kelly M
J HIV Ther; 2003 Feb; 8(1):11-4. PubMed ID: 12840709
[TBL] [Abstract][Full Text] [Related]
2. Switching effective antiretroviral therapy: a review.
Drechsler H; Powderly WG
Clin Infect Dis; 2002 Nov; 35(10):1219-30. PubMed ID: 12410482
[TBL] [Abstract][Full Text] [Related]
3. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
5. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
6. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
Müller AD; Myer L; Jaspan H
Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
[TBL] [Abstract][Full Text] [Related]
7. Once-daily therapies.
Carey D
J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708
[TBL] [Abstract][Full Text] [Related]
8. Benefits and concerns of simplification strategies in HIV-infected patients.
Negredo E; Bonjoch A; Clotet B
J Antimicrob Chemother; 2006 Aug; 58(2):235-42. PubMed ID: 16807250
[TBL] [Abstract][Full Text] [Related]
9. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
Bucher HC; Young J; Battegay M
J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
[TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy.
Suter F; Ghinelli F
Scand J Infect Dis Suppl; 2003; 106():82-5. PubMed ID: 15000592
[TBL] [Abstract][Full Text] [Related]
11. Switch strategies in patients on effective HAART.
Maggiolo F; Ripamonti D; Suter F
J Antimicrob Chemother; 2005 Jun; 55(6):821-3. PubMed ID: 15849261
[TBL] [Abstract][Full Text] [Related]
12. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
13. [Revised guideline "Antiretroviral Treatment"].
Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren
Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2399-405. PubMed ID: 16277129
[TBL] [Abstract][Full Text] [Related]
14. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
15. Treatment interruption in HIV therapy: a SMART strategy?
Jülg B; Goebel FD
Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
[TBL] [Abstract][Full Text] [Related]
16. The long-term consequences of antiretroviral therapy: a review.
Boyd M; Reiss P
J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
[No Abstract] [Full Text] [Related]
17. Improvements in antiretroviral therapy outcomes over calendar time.
Boyd MA
Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
[TBL] [Abstract][Full Text] [Related]
18. The long-term consequences of antiretroviral therapy.
Smith D
J HIV Ther; 2006 Jun; 11(2):24-5. PubMed ID: 16981592
[No Abstract] [Full Text] [Related]
19. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
Justesen US
Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
